Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
13 hedge funds and large institutions have $3.66M invested in Seelos Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
19% more capital invested
Capital invested by funds: $3.07M → $3.66M (+$587K)
35% less funds holding
Funds holding: 20 → 13 (-7)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$107K |
| 2 |
BlackRock
New York
|
+$88.2K |
| 3 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
+$7.67K |
| 4 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$7.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$451K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$75K |
| 3 |
VF
Virtu Financial
New York
|
-$68K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$63K |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$54K |
SEEL Hedge Fund Activity: Q4 2019 in Review
13 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2019, worth a combined $3.66M — up 19% from $3.07M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SEEL and 1 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $107K. The largest seller was Sabby Management, exiting entirely with an estimated $451K sold.
- 13 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2019, down from 20 in Q3 2019.
- Funds reported $3.66M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2019, up 19% quarter-over-quarter.
- 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2019 and 8 closed out, a net change of -7 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $107K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2019 was Sabby Management, an estimated $451K sold.
Based on aggregated 13F filings for Q4 2019.